The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Senators call on FDA to act against misleading weight-loss drug commercials
Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without disclosing safety and risk information.
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
The maximum semaglutide dose for weight loss ... injection pens is nearly impossible. Ozempic and Wegovy both have a starting dose of 0.25 milligrams per week. While this may sound small, this ...
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Their work found that for adults struggling with alcohol use disorder, weight loss drugs containing ... for the nine-week study – one group received weekly semaglutide injections and one ...
Wegovy is taken via an injection once a week. Should you meet the eligibility criteria ... GP about whether they are eligible for and should have a prescription for weight loss drugs. The ...
But it is difficult to compare the two treatments and, crucially, users of either drug can put weight back on once they stop ... Weight loss injection hype fuels online black market Watch: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback